@bina.capital: JNJ vs PFE: start with the reporting basis, then compare. Johnson & Johnson FY2025 ended Dec 28, 2025; Pfizer FY2025 ended Dec 31, 2025. Reported revenue was $94.193B / $62.579B. Gross margin, calculated from each company’s reported cost of sales, was 67.9% / 74.3%. Cost classifications differ: Pfizer reports intangible amortization separately, while JNJ includes it in cost of products sold. These margins are not fully like-for-like. Revenue CAGR from FY2021 to FY2025 was 4.6% / −6.3%. JNJ’s starting revenue is recast to continuing operations following the consumer-health separation. These are four annual growth intervals, not a prediction. Bina labels Johnson & Johnson an Anchor and Pfizer a Vault. That proprietary profile is not a safety rating or a stock recommendation. Figures from issuer/SEC reports, checked Oct 23, 2026. Educational only; not investment advice. https://dub.sh/5Og1t5x

Bina Capital

Open In TikTok:

Region: US

Monday 02 November 2026 21:01:01 GMT